Deutetrabenazine

(Austedo)

Deutetrabenazine

Drug updated on 11/13/2023

Dosage FormTablet (oral: 6 mg, 9 mg, 12 mg)
Drug ClassVesicular monoamine transporter 2 inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with chorea associated with Huntington’s disease.
  • For the treatment of adult patients with tardive dyskinesia.

Product Monograph / Prescribing Information

Document TitleYearSource
Austedo (deutetrabenazine) Prescribing Information.2022Teva Pharmaceuticals USA, Inc., Parsippany, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines